INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.

EyePoint shares fell $9.88, or 66.98%, to $4.87 on August 17, 2026, after its pivotal Phase 3 LUGANO trial for DURAVYU in wet AMD failed to meet its best-corrected visual-acuity endpoint versus Regeneron's 2 mg Eylea across the full dataset. Pomerantz LLP is investigating potential securities-fraud and other unlawful-business-practice claims involving EyePoint and certain officers or directors. The clinical setback materially weakens the near-term investment case for DURAVYU and adds litigation risk.

Analysis

The litigation notice itself is not incremental to EyePoint’s fundamental value; the relevant underwriting reset is that a depot-delivery candidate failed the efficacy bar against a high-standard anti-VEGF comparator. EYPT is now primarily a cash-runway and salvage-value situation: valuation depends on remaining development assets, the probability that subsequent LUGANO analyses identify a regulator-acceptable subgroup, and whether management must raise capital before a credible readout. After a ~67% one-day collapse, borrow costs, low liquidity, and potential retail short-covering make a fresh outright short unattractive without updated cash, debt, and trial-detail data.

For REGN, the competitive threat from a longer-duration vorolanib implant has diminished, modestly improving durability of Eylea franchise cash flows and supporting Eylea HD uptake versus alternative dosing-reduction approaches. The financial effect is likely immaterial in the next quarter but becomes more relevant over 6-18 months if other sustained-delivery AMD programs also encounter efficacy or safety limitations; this raises the strategic value of proven high-dose anti-VEGF dosing intervals. The larger risk to REGN remains broader biosimilar and retinal-market competition, not EYPT’s setback alone.

Consensus may overstate the legal headline’s importance and understate binary clinical/regulatory uncertainty. A lawsuit does not establish misconduct or create a near-term operating catalyst; any rebound in EYPT would require independently disclosed evidence of a clean responder subgroup, acceptable ocular safety, and sufficient liquidity to fund the path forward. Conversely, an at-the-market offering, going-concern language, or a second pivotal disappointment would likely drive another material leg down within 1-3 months.

Key Decisions for Investors

• Avoid initiating a new EYPT short at current distressed levels; instead, monitor the next 10-Q for unrestricted cash, quarterly burn, ATM capacity, and stated runway. Consider a tactical short only after a liquidity-driven rebound if management indicates financing is required within 12 months; cover on confirmed partnering/non-dilutive funding or regulator-supported subgroup development.
• Maintain or initiate a modest 6-18 month REGN overweight versus the XBI biotech ETF, rather than treating this as a standalone catalyst. The thesis is incremental retinal-franchise de-risking; invalidate if Eylea franchise guidance weakens materially, biosimilar erosion accelerates, or competing long-acting retinal products show superior pivotal efficacy.
• For event-driven accounts, set an EYPT alert around any full LUGANO presentation or regulatory update rather than buying post-crash optionality. Only reassess long exposure if subgroup effect size, discontinuation/safety data, and cash runway jointly support a viable pivotal or filing path; absent those data, apparent cheapness is not a valuation signal.
• Do not assign material value to the class-action investigation in either name. Revisit only if a filed complaint produces specific allegations tied to internal trial data, disclosure timing, or an SEC inquiry; until then, expected settlement and D&O costs are unlikely to drive EYPT’s enterprise value.